GET DAILY SIGNALSCardio Diagnostics Holdings (CDIO) Climbs +11.8% Over 30 Days as Recovery Takes Hold
Key Takeaways
- CDIO shares climbed roughly 11.8% over the past 30 days, rising from about $1.69 to $1.89.
- The gain reflects a recovery from early-November lows near $1.60 in a thinly traded micro-cap stock.
- Company updates, including a third-quarter filing and a new clinical whitepaper, coincided with the rebound.
- Over the broader quarter, the stock remains modestly lower versus its mid-August level near $2.01.
- Cardio Diagnostics is an early-stage molecular diagnostics company, with revenue still small relative to its market value.
- Low liquidity and a small float can amplify price swings in either direction.
Company Background and Market Position
Cardio Diagnostics Holdings, Inc. is a Chicago-based molecular diagnostics company founded in 2017 that develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its technology combines DNA methylation biomarkers with an AI-driven multi-omics engine to assess coronary heart disease risk from a blood sample. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company's flagship products include Epi+Gen CHD, a three-year risk assessment for coronary heart disease events such as heart attacks, and PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease. Its broader portfolio also includes HeartRisk, a software-as-a-service cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only solution supporting biopharmaceutical development. The company serves telemedicine providers, concierge and longevity clinics, risk-bearing provider organizations, and employers.
CDIO trades on the Nasdaq Capital Market as a micro-cap name, with a market capitalization of roughly $5.6 million and a small workforce of about 17 employees. Investors follow the stock for its exposure to precision cardiovascular diagnostics and AI-driven testing, while weighing the company's early-stage revenue base and ongoing capital requirements.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, CDIO shares advanced approximately 11.8%, moving from a closing price of about $1.69 to $1.89. The move was not a straight line: the stock slipped to intraday lows near $1.60 in early November before recovering through the middle of the month. From what I see, the rebound came after a period of weakness rather than a single dominant catalyst.
The broader quarter tells a different story. From a mid-August level near $2.01, the stock has drifted modestly lower to around $1.89, a decline of roughly 6%. The quarterly path was volatile, including a brief August rally toward the $2.17 area, a gradual September-to-October pullback, and a partial rebound in November. The overall three-month trend reflects sideways-to-lower trading punctuated by sharp, liquidity-driven swings.
Factors Behind the Recent 30-Day Move
The 30-day advance followed a period of weakness rather than a single dominant catalyst. After declining through much of October, CDIO found a floor near $1.60 in early November and subsequently recovered as a series of company announcements drew renewed attention. One thing that stands out is how modest news flow can move a thinly traded name like this.
Among the verified developments in the window were the filing of the company's third-quarter report for the period ended September 30, 2026, and the release of a new clinical whitepaper examining non-obstructive coronary artery disease and gaps in coronary angiography. The company has also been advancing its commercialization efforts, including the earlier launch of an in-house, high-complexity CLIA-certified laboratory in Iowa City and a payer coverage agreement with Atlas Healthcare Physicians for its Epi+Gen CHD and PrecisionCHD tests.
Because CDIO is a micro-cap with limited daily trading volume, modest order flow can produce outsized percentage moves. The recent rebound therefore reflects both incremental company news and a broader stabilization in sentiment following the October decline.
Drivers of Performance Over the Full Quarter
Over the full quarter, CDIO's performance has been shaped by the tension between commercialization progress and the financial realities of an early-stage diagnostics company. An August investor call and related announcements contributed to a brief rally, but gains were not sustained as the stock consolidated through September and October.
The longer-term narrative centers on the company's efforts to expand adoption of its blood-based cardiovascular tests among providers and employers, reduce costs through its in-house laboratory, and pursue international expansion. At the same time, the company has acknowledged an ongoing need to raise additional capital, which can weigh on sentiment through potential dilution. These competing forces have kept the stock range-bound on a quarterly basis even as day-to-day trading remains highly volatile.
Key Areas to Watch Going Forward
Looking ahead, several factors are likely to influence CDIO. The most important include the company's upcoming quarterly and annual results, which will provide updated figures on revenue, cash burn, and its capital position. Capital-raising activity remains a key consideration, given the company's stated need to fund operations and the potential for dilution.
On the commercial side, investors will monitor progress in onboarding providers and employers, expansion of payer coverage, and the ramp-up of the in-house laboratory. Regulatory context also matters, particularly the evolving oversight framework for laboratory-developed tests. Finally, as a micro-cap with thin liquidity, CDIO's shares remain sensitive to general market sentiment and sector rotation within biotechnology and diagnostics, which can amplify both gains and losses. I’m watching this closely for any updates on payer traction.
Exploring Tickeron’s AI Trading Bots
In my own research process, I often turn to Tickeron’s AI Trading Bots to get a sense of how automated strategies are positioned around names like this. The platform offers a range of bots that scan thousands of tickers using different timeframes and approaches, which can provide an additional data point when reviewing volatile micro-caps. It is useful for comparing systematic signals alongside fundamental developments without replacing personal analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CDIO's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CDIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 50 similar instances when the indicator left oversold territory. In 40 of the 50 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 41 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 21 of 38 cases over the following month. The odds of a continued upward trend are 55%.
CDIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 53 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement